Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Astellas Pharma
Biotech
Astellas ends $1.6B biobucks TCE pact with CytomX after 6 years
Astellas is ending its six-year, $1.6 billion biobuck partnership with CytomX Therapeutics aimed at exploring TCE bispecifics.
Will Maddox
Mar 16, 2026 10:12am
Evinova reels in AI partnerships with Astellas and AZ deals
Feb 24, 2026 12:00pm
Aviceda eye disease hopeful fails to top Astellas med in phase 2
Dec 15, 2025 2:14pm
GSK chief steps down in stunning move—Chutes & Ladders
Oct 3, 2025 8:30am
Astellas offers lab space to help Japanese biotechs 'go global'
Jun 13, 2025 4:41am
Astellas stops development of early-stage lymphoma CAR-T
Jan 9, 2025 6:49am
